Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N M Anstey

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
BMJ Open|August 24, 2014
Factors that are associated with the risk of acquiring Plasmodium knowlesi malaria in Sabah, Malaysia: a case-control study protocolM J Grigg, T William, C J Drakeley, et al.
Antimicrobial Agents and Chemotherapy|January 9, 2008
Determinants of in vitro drug susceptibility testing of Plasmodium vivaxB Russell, F Chalfein, B Prasetyorini, et al.
The Journal of Experimental Medicine|August 1, 1996
Nitric oxide in Tanzanian children with malaria: inverse relationship between malaria severity and nitric oxide production/nitric oxide synthase type 2 expressionN M Anstey, J B Weinberg, M Y Hassanali, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 15, 1992
Extensive genetic diversity in the HLA class II region of Africans, with a focally predominant allele, DRB1*1304A V Hill, C E Allsopp, D Kwiatkowski, et al.
Antimicrobial Agents and Chemotherapy|October 13, 2010
In vivo and in vitro efficacy of chloroquine against Plasmodium malariae and P. ovale in Papua, IndonesiaH Siswantoro, B Russell, A Ratcliff, et al.
Antimicrobial Agents and Chemotherapy|September 12, 2007
Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malariaR N Price, A R Hasugian, A Ratcliff, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 17, 2007
Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malariaA R Hasugian, H L E Purba, E Kenangalem, et al.
The Journal of Infectious Diseases|November 24, 1999
Nitric oxide synthase type 2 promoter polymorphisms, nitric oxide production, and disease severity in Tanzanian children with malariaM C Levesque, M R Hobbs, N M Anstey, et al.
The Journal of Infectious Diseases|September 24, 2008
Amplification of pvmdr1 associated with multidrug-resistant Plasmodium vivaxR Suwanarusk, M Chavchich, B Russell, et al.
Genes and Immunity|November 9, 2002
A promoter polymorphism in the gene encoding interleukin-12 p40 (IL12B) is associated with mortality from cerebral malaria and with reduced nitric oxide productionG Morahan, C S Boutlis, D Huang, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
BMJ Open|August 24, 2014
Factors that are associated with the risk of acquiring Plasmodium knowlesi malaria in Sabah, Malaysia: a case-control study protocolM J Grigg, T William, C J Drakeley, et al.
Antimicrobial Agents and Chemotherapy|January 9, 2008
Determinants of in vitro drug susceptibility testing of Plasmodium vivaxB Russell, F Chalfein, B Prasetyorini, et al.
The Journal of Experimental Medicine|August 1, 1996
Nitric oxide in Tanzanian children with malaria: inverse relationship between malaria severity and nitric oxide production/nitric oxide synthase type 2 expressionN M Anstey, J B Weinberg, M Y Hassanali, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 15, 1992
Extensive genetic diversity in the HLA class II region of Africans, with a focally predominant allele, DRB1*1304A V Hill, C E Allsopp, D Kwiatkowski, et al.
Antimicrobial Agents and Chemotherapy|October 13, 2010
In vivo and in vitro efficacy of chloroquine against Plasmodium malariae and P. ovale in Papua, IndonesiaH Siswantoro, B Russell, A Ratcliff, et al.
Antimicrobial Agents and Chemotherapy|September 12, 2007
Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malariaR N Price, A R Hasugian, A Ratcliff, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 17, 2007
Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malariaA R Hasugian, H L E Purba, E Kenangalem, et al.
The Journal of Infectious Diseases|November 24, 1999
Nitric oxide synthase type 2 promoter polymorphisms, nitric oxide production, and disease severity in Tanzanian children with malariaM C Levesque, M R Hobbs, N M Anstey, et al.
The Journal of Infectious Diseases|September 24, 2008
Amplification of pvmdr1 associated with multidrug-resistant Plasmodium vivaxR Suwanarusk, M Chavchich, B Russell, et al.
Genes and Immunity|November 9, 2002
A promoter polymorphism in the gene encoding interleukin-12 p40 (IL12B) is associated with mortality from cerebral malaria and with reduced nitric oxide productionG Morahan, C S Boutlis, D Huang, et al.
Pageof 6